bph corporate [asx: bph] asx announcementbphenergy.com.au/documents/melanoma symposium +...
TRANSCRIPT
BPH Corporate Limited ACN 95 912 002 PO Box 317, North Perth Western Australia 6906
14 View Street, North Perth Western Australia 6006 [email protected] www.biopharmica.com.au
T: +61 8 9328 8366 F: +61 8 9328 8733
BPH Corporate [ASX: BPH] ASX Announcement
9 November 2010 Companies Announcements Office Australian Securities Exchange Limited 10th Floor, 20 Bond Street SYDNEY NSW 2000
DR ROBIN SCAIFE TO PRESENT AT MELANOMA SYMPOSIUM TODAY BPH Corporate Limited [ASX: BPH] is pleased to attach the presentation that Principal Researcher Dr Robin Scaife has been invited by the Scott Kirkbride Melanoma Research Centre (SKMRC) to give at the Melanoma Symposium in Perth today.
Dr Scaife was recently awarded a highly prestigious discovery grant which is due to start in January 2011. The SKMRC supports research that is aimed at providing crucial breakthroughs for improved diagnosis and treatment of melanomas. Dr Scaife’s presentation details innovative strategies to identify new drug leads to target melanoma cells.
Although melanomas have a reputation for being particularly refractory to therapeutic intervention, some types of melanoma have recently been shown to respond well to a new class of customized cancer drugs. Dr Scaife and his collaborators at Western Australian Institute for Medical Research (WAIMR) and the University of Western Australia are using the high-content imaging and analysis platform at Molecular Discovery Systems to screen a significant new resource of new drug-like molecules for inhibitors of melanoma cell survival and proliferation. Also presenting is Dr Louise Winteringham, who as a direct result of the SKMRC grant has been leading a team at WAIMR investigating the tumor suppressor gene HLS5 and its potential influence in melanoma. Dr Winteringham said “through their research they are showing that HLS5 is targeting one of the pathways in Melanoma”. BPH has been investing in the tumor suppressor gene ‘HLS5’ project since it was reported by WAIMR Director Professor Peter Klinken in 2004. Yours sincerely,
David Breeze Chairman For more information contact: Mr David Breeze, Chairman BPH Corporate Limited Tel : +61 8 9328 8366
Identification of New Drug
Leads to Target Melanoma
Cells
Dr Robin Scaife
Molecular Discovery Systems
WAIMR
Chemotherapies
Progressive
Responsive
(10-15%)
Khan et al., Cancer Control (2006)
Ap
op
tos
isD
rug
eff
lux
Lee et al., PCM Res (2010)
PLX-4032
BRAF V600ET
(80% responsive)
Mitotic Drugs
Jordan et al., Cancer Res (1996)
Nigg, Nature Reviews (2001)
Taxol
Metaphase
Anaphase
Mitotic Arrest
23h
23.5h
24h
24.5h
HeLa1 µ µµµMTaxol
DMSO
1 µ µµµMTaxol
Anti-β-tubulin/GFP-H2B
020
4060
8010
0
14710131619
prem
itosis
mito
sis
x 30minutes
Mitotic Slippage
14.5h
17.5h
24.5h
44h
10 nMTaxol
10 nMTaxol
Anti-β-tubulin/GFP-H2B
020
40
60
80
100
147
10
13
16
19
pre
mit
mitosis1
postm
it1
postm
it2
postm
it3
mitosis2
postm
it4
10 nMTx
x 30min
Exit
Death signalMitotic signal
Time
Death
Induction of Mitotic Death
0
0.2
0.4
0.6
0.81
1.2
E10
Plate 5
Antibody signal
TX+ DMSO
TX+5E10
TX+ DMSO
TX+5E10
GFP-H2B
Apopto
sis
TX+5E10
Cell Line Variation
DLD-1
HT-29
Longley et al., AACR (2006)
Gascoigne et al., Cancer Cell (2008)
Gascoigne et al., Cancer Cell
(2008)
Mitotic signalDeath signal
DLD-1 Time
Death
Exit
SAC-independent death
Huang et al., Cancer Cell (2009)
siRNA
SAC
Cdc20
APC/C
Mitotic Arrest
CyclinB1/CDK1
Spindle drugs
High-content Screening
Apopto
sis
SAC
APC/C
Cdk15E10
APCi
New Melanoma Drug Leads